Personalized Care in the Era of Personalized Medicine
At START we strive to provide personal care for our patients and to our research sponsors. Each patient has a personal physician, and each clinical study has our personal involvement. We emphasize quality in patient care, data management, and scientific input. Our personalized-medicine approach includes array comparative genomic hybridization, and Sequenom characterization of patient’s tumor specimens in our attempt to find the right medicine for the right patient.
Transforming Early Clinical Trials
The mission of START is to accelerate the development of new agents for the treatment and eventual cure of cancer. With our state-of-the-art clinical research centers in San Antonio, Madrid and Shanghai, we can help our patients find the most innovative and promising new cancer agents currently undergoing early clinical development.
A World Leader in Drug Development Expertise
Evaluating the safety of new agents requires considerable expertise and training. At START, our Principal Investigators have experience measured in decades, not months. We limit the number of sub-investigators involved in a study to ensure that we can report considerable “hands-on” experience with the safety of your new agent.
Innovative Information Technology
Clinical data should inform both the physician and our sponsors in real-time, not in 30 days. START has pioneered real-time delivery of clinical trial data via our web portal. Just one click allows you to see vital signs, laboratory data, toxicity and adverse events, and ECGs.
Remote data monitoring is available. Reduce the expense of monthly monitoring visits and improve quality and efficiency. Ask us how you can use this feature